Shopping Cart 0
Cart Subtotal
USD 0

Hematology Reagents - Medical Devices Pipeline Assessment, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Hematology Reagents-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Hematology Reagents-Medical Devices Pipeline Assessment, 2018" provides an overview of Hematology Reagents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hematology Reagents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Hematology Reagents under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Hematology Reagents and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Hematology Reagents under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Hematology Reagents Overview 7

3 Products under Development 8

3.1 Hematology Reagents-Pipeline Products by Stage of Development 8

3.2 Hematology Reagents-Pipeline Products by Segment 9

3.3 Hematology Reagents-Pipeline Products by Territory 10

3.4 Hematology Reagents-Pipeline Products by Regulatory Path 11

3.5 Hematology Reagents-Pipeline Products by Estimated Approval Date 12

4 Hematology Reagents-Pipeline Products under Development by Companies 13

4.1 Hematology Reagents Companies-Pipeline Products by Stage of Development 13

4.2 Hematology Reagents-Pipeline Products by Stage of Development 14

5 Hematology Reagents Companies and Product Overview 15

5.1 Analyticon Biotechnologies AG Company Overview 15

5.2 Cellphire Inc Company Overview 21

5.3 CPSI Biotech Company Overview 22

5.4 Instrumentation Laboratory Company Overview 23

5.5 Quotient Limited Company Overview 26

5.6 Streck Inc Company Overview 30

5.7 University of California Los Angeles Company Overview 34

6 Hematology Reagents- Recent Developments 35

6.1 Jun 12, 2018: Change at the top of the Segment Advanced Therapies at Siemens Healthineers 35

6.2 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 35

6.3 Jun 01, 2018: ISBT Satellite Symposium Co-hosted by Ortho Clinical Diagnostics and Quotient Discusses Responding to the Challenges of Resource Constraints in Transfusion Diagnostics 36

6.4 May 29, 2018: Quotient Names Franz Walt As Chief Executive Officer 37

6.5 May 29, 2018: Quotient Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ European Field Trials 38

6.6 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 39

6.7 May 23, 2018: Swift Biosciences Builds on Momentum, Accelerates Growth with Addition of Nathan Wood as New CEO 42

6.8 May 14, 2018: Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents 43

6.9 May 14, 2018: Boule Diagnostics Interim report January-March 2018 43

6.10 May 09, 2018: Accelerate Diagnostics reports Q1 2018 financial results 44

6.11 May 09, 2018: Sysmex Group Formulates New Long-Term Management Goals 45

6.12 May 09, 2018: Sysmex Announces Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2018 47

6.13 May 08, 2018: Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief Technology Officer 50

6.14 May 08, 2018: Bio-Rad Announces First Quarter 2018 Financial Results 51

6.15 May 08, 2018: Haemonetics Reports 4th Quarter and Fiscal Year 2018 Results and Provides Fiscal 2019 Guidance 51

6.16 May 08, 2018: Ortho Clinical Diagnostics Holds Summit to Help Asia-Pacific Lab Leaders Envision the Lab of the Future 53

6.17 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 53

6.18 May 07, 2018: Instrumentation Laboratory Worldwide Sales Top USD970 M In 2017 54

6.19 May 03, 2018: Siemens Healthineers fully on track to meet the targets 55

7 Appendix 127

7.1 Methodology 127

7.2 About GlobalData 130

7.3 Contact Us 130

7.4 Disclaimer 130


List Of Figure

1.2 List of Figures

Figure 1: Hematology Reagents-Pipeline Products by Stage of Development 8

Figure 2: Hematology Reagents-Pipeline Products by Segment 9

Figure 3: Hematology Reagents-Pipeline Products by Territory 10

Figure 4: Hematology Reagents-Pipeline Products by Regulatory Path 11

Figure 5: Hematology Reagents-Pipeline Products by Estimated Approval Date 12


List Of Table

1.1 List of Tables

Table 1: Hematology Reagents-Pipeline Products by Stage of Development 8

Table 2: Hematology Reagents-Pipeline Products by Segment 9

Table 3: Hematology Reagents-Pipeline Products by Territory 10

Table 4: Hematology Reagents-Pipeline Products by Regulatory Path 11

Table 5: Hematology Reagents-Pipeline Products by Estimated Approval Date 12

Table 6: Hematology Reagents Companies-Pipeline Products by Stage of Development 13

Table 7: Hematology Reagents-Pipeline Products by Stage of Development 14

Table 8: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: Fluitest IRON B Reagent-Product Status 15

Table 10: Fluitest IRON B Reagent-Product Description 16

Table 11: Hemolyzer-5-Diff 5P-Product Status 16

Table 12: Hemolyzer-5-Diff 5P-Product Description 16

Table 13: Hemolyzer-5-Diluent-Product Status 17

Table 14: Hemolyzer-5-Diluent-Product Description 17

Table 15: Hemolyzer-3-Cleaner-Product Status 17

Table 16: Hemolyzer-3-Cleaner-Product Description 18

Table 17: Hemolyzer-3-Diluent-Product Status 18

Table 18: Hemolyzer-3-Diluent-Product Description 18

Table 19: Hemolyzer-3-Lyser-Product Status 19

Table 20: Hemolyzer-3-Lyser-Product Description 19

Table 21: Hemolyzer-5-Lyser-Product Status 19

Table 22: Hemolyzer-5-Lyser-Product Description 20

Table 23: Turbitex FER Reagent-Product Status 20

Table 24: Turbitex FER Reagent-Product Description 20

Table 25: Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 21

Table 26: Thrombogent-Product Status 21

Table 27: Thrombogent-Product Description 21

Table 28: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 22

Table 29: FACSGuard-Product Status 22

Table 30: FACSGuard-Product Description 22

Table 31: Instrumentation Laboratory Company Pipeline Products & Ongoing Clinical Trials Overview 23

Table 32: HemosIL AcuStar Multi-Ab Controls-Product Status 23

Table 33: HemosIL AcuStar Multi-Ab Controls-Product Description 23

Table 34: HemosIL Dabigatran Calibrators-Product Status 24

Table 35: HemosIL Dabigatran Calibrators-Product Description 24

Table 36: HemosIL Dabigatran Controls-Product Status 24

Table 37: HemosIL Dabigatran Controls-Product Description 25

Table 38: HemosIL Rivaroxaban Calibrators-Product Status 25

Table 39: HemosIL Rivaroxaban Calibrators-Product Description 25

Table 40: Quotient Limited Pipeline Products & Ongoing Clinical Trials Overview 26

Table 41: ALBAcyte Antibody Identification Cells-B-Product Status 26

Table 42: ALBAcyte Antibody Identification Cells-B-Product Description 26

Table 43: ALBAcyte Rh-Screening Cells-Product Status 27

Table 44: ALBAcyte Rh-Screening Cells-Product Description 27

Table 45: ALBAcyte Screening Cells (2 cell)-Product Status 27

Table 46: ALBAcyte Screening Cells (2 cell)-Product Description 27

Table 47: Anti-Human C3 Globulin Reagent-Product Status 28

Table 48: Anti-Human C3 Globulin Reagent-Product Description 28

Table 49: Complement Coated Cells-Product Status 28

Table 50: Complement Coated Cells-Product Description 28

Table 51: WARM Antibody Removal Reagent-Product Status 29

Table 52: WARM Antibody Removal Reagent-Product Description 29

Table 53: Streck Inc Pipeline Products & Ongoing Clinical Trials Overview 30

Table 54: CD-Chex CD103 Plus-Product Status 30

Table 55: CD-Chex CD103 Plus-Product Description 31

Table 56: CD-Chex CD117 Plus-Product Status 31

Table 57: CD-Chex CD117 Plus-Product Description 31

Table 58: CD-Chex Select-Product Status 32

Table 59: CD-Chex Select-Product Description 32

Table 60: CD-Chex TdT Plus-Product Status 32

Table 61: CD-Chex TdT Plus-Product Description 33

Table 62: LBC-Chex-Product Status 33

Table 63: LBC-Chex-Product Description 33

Table 64: University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 34

Table 65: Rh (D) Human Blood Typing Reagent-Product Status 34

Table 66: Rh (D) Human Blood Typing Reagent-Product Description 34

Table 67: Glossary 129

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Analyticon Biotechnologies AG, Fluitest IRON B Reagent; Analyticon Biotechnologies AG, Hemolyzer - 5 - Diff 5P; Analyticon Biotechnologies AG, Hemolyzer - 5 - Diluent; Analyticon Biotechnologies AG, Hemolyzer-3-Cleaner; Analyticon Biotechnologies AG, Hemolyzer-3-Diluent; Analyticon Biotechnologies AG, Hemolyzer-3-Lyser; Analyticon Biotechnologies AG, Hemolyzer-5-Lyser; Analyticon Biotechnologies AG, Turbitex FER Reagent; Cellphire Inc, Thrombogent; CPSI Biotech, FACSGuard; Instrumentation Laboratory Company, HemosIL AcuStar Multi-Ab Controls; Instrumentation Laboratory Company, HemosIL Dabigatran Calibrators; Instrumentation Laboratory Company, HemosIL Dabigatran Controls; Instrumentation Laboratory Company, HemosIL Rivaroxaban Calibrators; Quotient Limited, ALBAcyte Antibody Identification Cells - B; Quotient Limited, ALBAcyte Rh - Screening Cells; Quotient Limited, ALBAcyte Screening Cells (2 cell); Quotient Limited, Anti-Human C3 Globulin Reagent; Quotient Limited, Complement Coated Cells; Quotient Limited, WARM Antibody Removal Reagent; Streck Inc, CD-Chex CD103 Plus; Streck Inc, CD-Chex CD117 Plus; Streck Inc, CD-Chex Select; Streck Inc, CD-Chex TdT Plus; Streck Inc, LBC-Chex; University of California Los Angeles, Rh (D) Human Blood Typing Reagent


Companies

Analyticon Biotechnologies AG

Cellphire Inc

CPSI Biotech

Instrumentation Laboratory

Quotient Limited

Streck Inc

University of California Los Angeles

Hematology Reagents-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Hematology Reagents-Medical Devices Pipeline Assessment, 2018" provides an overview of Hematology Reagents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hematology Reagents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Hematology Reagents under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Hematology Reagents and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Hematology Reagents under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Hematology Reagents Overview 7

3 Products under Development 8

3.1 Hematology Reagents-Pipeline Products by Stage of Development 8

3.2 Hematology Reagents-Pipeline Products by Segment 9

3.3 Hematology Reagents-Pipeline Products by Territory 10

3.4 Hematology Reagents-Pipeline Products by Regulatory Path 11

3.5 Hematology Reagents-Pipeline Products by Estimated Approval Date 12

4 Hematology Reagents-Pipeline Products under Development by Companies 13

4.1 Hematology Reagents Companies-Pipeline Products by Stage of Development 13

4.2 Hematology Reagents-Pipeline Products by Stage of Development 14

5 Hematology Reagents Companies and Product Overview 15

5.1 Analyticon Biotechnologies AG Company Overview 15

5.2 Cellphire Inc Company Overview 21

5.3 CPSI Biotech Company Overview 22

5.4 Instrumentation Laboratory Company Overview 23

5.5 Quotient Limited Company Overview 26

5.6 Streck Inc Company Overview 30

5.7 University of California Los Angeles Company Overview 34

6 Hematology Reagents- Recent Developments 35

6.1 Jun 12, 2018: Change at the top of the Segment Advanced Therapies at Siemens Healthineers 35

6.2 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 35

6.3 Jun 01, 2018: ISBT Satellite Symposium Co-hosted by Ortho Clinical Diagnostics and Quotient Discusses Responding to the Challenges of Resource Constraints in Transfusion Diagnostics 36

6.4 May 29, 2018: Quotient Names Franz Walt As Chief Executive Officer 37

6.5 May 29, 2018: Quotient Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ European Field Trials 38

6.6 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 39

6.7 May 23, 2018: Swift Biosciences Builds on Momentum, Accelerates Growth with Addition of Nathan Wood as New CEO 42

6.8 May 14, 2018: Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents 43

6.9 May 14, 2018: Boule Diagnostics Interim report January-March 2018 43

6.10 May 09, 2018: Accelerate Diagnostics reports Q1 2018 financial results 44

6.11 May 09, 2018: Sysmex Group Formulates New Long-Term Management Goals 45

6.12 May 09, 2018: Sysmex Announces Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2018 47

6.13 May 08, 2018: Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief Technology Officer 50

6.14 May 08, 2018: Bio-Rad Announces First Quarter 2018 Financial Results 51

6.15 May 08, 2018: Haemonetics Reports 4th Quarter and Fiscal Year 2018 Results and Provides Fiscal 2019 Guidance 51

6.16 May 08, 2018: Ortho Clinical Diagnostics Holds Summit to Help Asia-Pacific Lab Leaders Envision the Lab of the Future 53

6.17 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 53

6.18 May 07, 2018: Instrumentation Laboratory Worldwide Sales Top USD970 M In 2017 54

6.19 May 03, 2018: Siemens Healthineers fully on track to meet the targets 55

7 Appendix 127

7.1 Methodology 127

7.2 About GlobalData 130

7.3 Contact Us 130

7.4 Disclaimer 130


List Of Figure

1.2 List of Figures

Figure 1: Hematology Reagents-Pipeline Products by Stage of Development 8

Figure 2: Hematology Reagents-Pipeline Products by Segment 9

Figure 3: Hematology Reagents-Pipeline Products by Territory 10

Figure 4: Hematology Reagents-Pipeline Products by Regulatory Path 11

Figure 5: Hematology Reagents-Pipeline Products by Estimated Approval Date 12


List Of Table

1.1 List of Tables

Table 1: Hematology Reagents-Pipeline Products by Stage of Development 8

Table 2: Hematology Reagents-Pipeline Products by Segment 9

Table 3: Hematology Reagents-Pipeline Products by Territory 10

Table 4: Hematology Reagents-Pipeline Products by Regulatory Path 11

Table 5: Hematology Reagents-Pipeline Products by Estimated Approval Date 12

Table 6: Hematology Reagents Companies-Pipeline Products by Stage of Development 13

Table 7: Hematology Reagents-Pipeline Products by Stage of Development 14

Table 8: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: Fluitest IRON B Reagent-Product Status 15

Table 10: Fluitest IRON B Reagent-Product Description 16

Table 11: Hemolyzer-5-Diff 5P-Product Status 16

Table 12: Hemolyzer-5-Diff 5P-Product Description 16

Table 13: Hemolyzer-5-Diluent-Product Status 17

Table 14: Hemolyzer-5-Diluent-Product Description 17

Table 15: Hemolyzer-3-Cleaner-Product Status 17

Table 16: Hemolyzer-3-Cleaner-Product Description 18

Table 17: Hemolyzer-3-Diluent-Product Status 18

Table 18: Hemolyzer-3-Diluent-Product Description 18

Table 19: Hemolyzer-3-Lyser-Product Status 19

Table 20: Hemolyzer-3-Lyser-Product Description 19

Table 21: Hemolyzer-5-Lyser-Product Status 19

Table 22: Hemolyzer-5-Lyser-Product Description 20

Table 23: Turbitex FER Reagent-Product Status 20

Table 24: Turbitex FER Reagent-Product Description 20

Table 25: Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 21

Table 26: Thrombogent-Product Status 21

Table 27: Thrombogent-Product Description 21

Table 28: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 22

Table 29: FACSGuard-Product Status 22

Table 30: FACSGuard-Product Description 22

Table 31: Instrumentation Laboratory Company Pipeline Products & Ongoing Clinical Trials Overview 23

Table 32: HemosIL AcuStar Multi-Ab Controls-Product Status 23

Table 33: HemosIL AcuStar Multi-Ab Controls-Product Description 23

Table 34: HemosIL Dabigatran Calibrators-Product Status 24

Table 35: HemosIL Dabigatran Calibrators-Product Description 24

Table 36: HemosIL Dabigatran Controls-Product Status 24

Table 37: HemosIL Dabigatran Controls-Product Description 25

Table 38: HemosIL Rivaroxaban Calibrators-Product Status 25

Table 39: HemosIL Rivaroxaban Calibrators-Product Description 25

Table 40: Quotient Limited Pipeline Products & Ongoing Clinical Trials Overview 26

Table 41: ALBAcyte Antibody Identification Cells-B-Product Status 26

Table 42: ALBAcyte Antibody Identification Cells-B-Product Description 26

Table 43: ALBAcyte Rh-Screening Cells-Product Status 27

Table 44: ALBAcyte Rh-Screening Cells-Product Description 27

Table 45: ALBAcyte Screening Cells (2 cell)-Product Status 27

Table 46: ALBAcyte Screening Cells (2 cell)-Product Description 27

Table 47: Anti-Human C3 Globulin Reagent-Product Status 28

Table 48: Anti-Human C3 Globulin Reagent-Product Description 28

Table 49: Complement Coated Cells-Product Status 28

Table 50: Complement Coated Cells-Product Description 28

Table 51: WARM Antibody Removal Reagent-Product Status 29

Table 52: WARM Antibody Removal Reagent-Product Description 29

Table 53: Streck Inc Pipeline Products & Ongoing Clinical Trials Overview 30

Table 54: CD-Chex CD103 Plus-Product Status 30

Table 55: CD-Chex CD103 Plus-Product Description 31

Table 56: CD-Chex CD117 Plus-Product Status 31

Table 57: CD-Chex CD117 Plus-Product Description 31

Table 58: CD-Chex Select-Product Status 32

Table 59: CD-Chex Select-Product Description 32

Table 60: CD-Chex TdT Plus-Product Status 32

Table 61: CD-Chex TdT Plus-Product Description 33

Table 62: LBC-Chex-Product Status 33

Table 63: LBC-Chex-Product Description 33

Table 64: University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 34

Table 65: Rh (D) Human Blood Typing Reagent-Product Status 34

Table 66: Rh (D) Human Blood Typing Reagent-Product Description 34

Table 67: Glossary 129

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Analyticon Biotechnologies AG, Fluitest IRON B Reagent; Analyticon Biotechnologies AG, Hemolyzer - 5 - Diff 5P; Analyticon Biotechnologies AG, Hemolyzer - 5 - Diluent; Analyticon Biotechnologies AG, Hemolyzer-3-Cleaner; Analyticon Biotechnologies AG, Hemolyzer-3-Diluent; Analyticon Biotechnologies AG, Hemolyzer-3-Lyser; Analyticon Biotechnologies AG, Hemolyzer-5-Lyser; Analyticon Biotechnologies AG, Turbitex FER Reagent; Cellphire Inc, Thrombogent; CPSI Biotech, FACSGuard; Instrumentation Laboratory Company, HemosIL AcuStar Multi-Ab Controls; Instrumentation Laboratory Company, HemosIL Dabigatran Calibrators; Instrumentation Laboratory Company, HemosIL Dabigatran Controls; Instrumentation Laboratory Company, HemosIL Rivaroxaban Calibrators; Quotient Limited, ALBAcyte Antibody Identification Cells - B; Quotient Limited, ALBAcyte Rh - Screening Cells; Quotient Limited, ALBAcyte Screening Cells (2 cell); Quotient Limited, Anti-Human C3 Globulin Reagent; Quotient Limited, Complement Coated Cells; Quotient Limited, WARM Antibody Removal Reagent; Streck Inc, CD-Chex CD103 Plus; Streck Inc, CD-Chex CD117 Plus; Streck Inc, CD-Chex Select; Streck Inc, CD-Chex TdT Plus; Streck Inc, LBC-Chex; University of California Los Angeles, Rh (D) Human Blood Typing Reagent


Companies

Analyticon Biotechnologies AG

Cellphire Inc

CPSI Biotech

Instrumentation Laboratory

Quotient Limited

Streck Inc

University of California Los Angeles